论文部分内容阅读
目的:观察益智方联合西药治疗脑梗死的临床疗效及其对患者肾功能的影响。方法:选取本院收治的80例脑梗死患者为研究对象,采用随机数字表法分为观察组和对照组各40例。对照组给予阿托伐他汀钙片与阿司匹林肠溶片治疗,观察组在对照组用药基础上加用自拟益智方治疗,2组均治疗3疗程。比较2组临床疗效,以及治疗前后内皮细胞上清液一氧化氮(NO)、内皮素-1(ET-1)的含量,比较2组治疗前后的美国国立卫生研究院卒中量表(NIHSS)与日常生活能力(MBI)评分,检测2组血清胱抑素C(Cys C)和血尿素氮(BUN)水平,观察2组不良反应发生情况。结果:总有效率观察组为90.00%,高于对照组的72.50%,2组比较,差异有统计学意义(P<0.05)。治疗前,2组NO、ET-1、Cys C、BUN水平比较,差异均无统计学意义(P>0.05)。治疗后,2组NO、ET-1、Cys C、BUN水平均较治疗前降低(P<0.05),观察组4项指标的水平均低于对照组(P<0.05)。治疗前,2组NIHSS及MBI评分比较,差异均无统计学意义(P>0.05)。治疗后,2组NIHSS评分均较治疗前降低(P<0.05),MBI评分均较治疗前升高(P<0.05),观察组的NIHSS评分低于对照组(P<0.05),MBI评分高于对照组(P<0.05)。治疗期间2组均无不良反应情况发生。结论:采用益智方联合西药治疗脑梗死患者,可有效改善患者的内皮细胞损伤、肾功能、神经受损状况以及提高患者日常生活能力,且用药安全。
Objective: To observe the clinical efficacy of Yizhi decoction combined with Western medicine in treating cerebral infarction and its effect on renal function. Methods: Eighty patients with cerebral infarction admitted to our hospital were selected as the research object and randomly divided into observation group (40 cases) and control group (40 cases). The control group was given atorvastatin calcium tablets and aspirin enteric-coated tablets. The observation group was treated with Yizhi Fang on the basis of the control group. Both groups were treated for 3 cycles. The clinical efficacy and the content of nitric oxide (NO) and endothelin-1 (ET-1) in the supernatant of the two groups before and after treatment were compared. The NIH Stroke Scale (NIHSS) (MBI), serum Cys C and BUN levels were measured in two groups. The occurrence of adverse reactions in two groups were observed. Results: The total effective observation group was 90.00%, higher than 72.50% in the control group, the difference was statistically significant (P <0.05). Before treatment, there was no significant difference in the levels of NO, ET-1, Cys C and BUN between the two groups (P> 0.05). After treatment, the levels of NO, ET-1, Cys C and BUN in two groups were lower than those before treatment (P <0.05). The levels of four indexes in the observation group were lower than those in the control group (P <0.05). Before treatment, there was no significant difference in NIHSS and MBI score between the two groups (P> 0.05). After treatment, the NIHSS scores in both groups were significantly lower than those before treatment (P <0.05), MBI scores were higher than those before treatment (P <0.05), NIHSS scores in the observation group were lower than those in the control group (P <0.05) In the control group (P <0.05). No adverse reactions occurred in the two groups during the treatment. Conclusion: The treatment of cerebral infarction with Yizhi decoction combined with Western medicine can effectively improve the endothelial cell injury, renal function, nerve damage and improve the daily living ability of patients, and the medication is safe.